Description
Product Usage Information
Western Blotting: 1:1000
Simple Western™: 1:10 - 1:50
Immunohistochemistry (Paraffin): 1:400 - 1:1600
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 34392 .
Protocol
Available protocols: Western Blotting, Immunohistochemistry (Paraffin)
Specificity / Sensitivity
ApoE4 (E5M4L) Rabbit Monoclonal Antibody recognizes endogenous levels of total ApoE4 protein. This antibody does not cross-react with ApoE2 or ApoE3 by western blot and is not expected to cross-react with endogenous ApoE2 or ApoE3 by immunohistochemistry. Non-specific staining was observed in kidney by immunohistochemistry.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg130 of human ApoE4 protein.
Background
Apolipoproteins are plasma lipoproteins that function as transporters of lipids and cholesterol in the circulatory system. Chylomicrons are a fundamental class of apolipoproteins containing very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) (1,2). Human ApoE has three isoforms: ApoE2, ApoE3, and ApoE4. These three isoforms differ in the combination of cysteine and arginine residues located at positions 130 and 176. The ApoE4 isoform contains arginine at both locations. Research studies have linked ApoE4 function to neuronal plasticity, synaptogenesis, and neurodegenerative diseases (3). ApoE4 is produced in the liver and brain, although it is widely expressed in other tissues, such as the lung, spleen, and ovary. Investigators have established the ApoE4 allele as a genetic risk factor for Alzheimer's disease (AD), accounting for 50-60% of the genetic variation in the disease (4). Research studies indicate that patients expressing ApoE4 have a reduced capacity for synaptic plasticity, an earlier age of onset of AD, and an increase in amyloid-beta (Aβ) deposition. The increase in Aβ suggests a role for ApoE4 in the impairment of amyloid clearance (5).
Alternate Names
AD2; Apo-E; APOE; Apolipoprotein E; LDLCQ5; LPG; MGC1571
